MLICM
ORMP icon

Metropolitan Life Insurance Company (MetLife)’s Oramed Pharmaceuticals ORMP Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,979
Closed -$17.1K – 2416
2022
Q1 		$17.1K Sell
1,979
-6,407
-76% -$65.6K ﹤0.01% 2158
2021
Q4 		$120K Hold
8,386
– – ﹤0.01% 2369
2021
Q3 		$184K Hold
8,386
– – ﹤0.01% 2141
2021
Q2 		$112K Buy
+8,386
New +$95.9K ﹤0.01% 2536

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ORMP Position: Q2 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 1,979 shares — an estimated $17.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ORMP in Q2 2021 and held it in 4 quarters. The position peaked at $184K in Q3 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,979 Oramed Pharmaceuticals shares in Q2 2022, an estimated $17.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Oramed Pharmaceuticals position peaked at $184K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2022, filed 11 Aug 2022.